Summary

for people ages 18 years and up (full criteria)
at UC Irvine
study started
estimated completion
Elizabeth Brem, MD(uci)

Description

Summary

A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory EBV+ lymphomas.

Official Title

A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered VRx-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies

Details

The purpose of this study is to determine whether VRx-3996 in combination with valganciclovir is safe, determine the side effect profile, and to determine whether this therapy may help patients with EBV-related lymphomas. The study has two phases. Goals of the first phase include determining a safe and tolerable dose that can be administered in phase 2. Goals of the second phase include further evaluating the safety and tolerability of VRx-3996 in combination with valganciclovir, evaluating how the drugs are metabolized in the body, evaluating response rates and other exploratory objectives that will help the researchers evaluate how these drugs work in the body. Participants will receive daily oral doses of the two study drugs and will have multiple study visits where they will have blood collected, physical examinations, and other medical monitoring.

Keywords

Epstein-Barr Virus Associated Lymphoma Lymphoproliferative Disorders EBV+ post-transplant lymphoproliferative malignancy EBV-associated lymphoproliferative disorders associated with acquired immunodeficiency including HIV-positive Relapsed, refractory, EBV+ lymphoid malignancy Neoplasms Valganciclovir VRx-3996

Eligibility

For people ages 18 years and up

Key Inclusion Criteria:

  • Relapsed/refractory, pathologically confirmed EBV+ lymphoid malignancy or lymphoproliferative disease
  • Absence of available therapy with reasonable likelihood of cure or significant clinical benefit
  • Adequate hematologic, hepatic and renal function as defined by laboratory assessment

Key Exclusion Criteria:

  • Known primary CNS lymphoma
  • Known CNS metastases or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks
  • Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
  • Refractory graft versus host disease (GvHD) not responding to treatment
  • Known active hepatitis B virus infection
  • Circulating hepatitis C virus on qPCR

Locations

  • UC Irvine Chao Family Comprehensive Cancer Center accepting new patients
    Orange California 92868 United States
  • USC Norris Comprehensive Cancer Center accepting new patients
    Los Angeles California 90033 United States

Lead Scientist

  • Elizabeth Brem, MD (uci)
    Assistant Health Sciences Professor, Medicine. Authored (or co-authored) 8 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Viracta Therapeutics, Inc.
Links
Viracta Therapeutics, Inc.
ID
NCT03397706
Phase
Phase 1/2
Study Type
Interventional
Last Updated